Phase 4 Psoriatic Arthritis Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with active psoriatic arthritis by a rheumatologist or other healthcare professional experienced in treating this condition.
• People with a Body Mass Index (BMI) of 30 or above (classified as obese), or a BMI between 27 and below 30 (classified as overweight) who also have at least one of the following health conditions: high blood pressure, high cholesterol or triglycerides, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.
• People who have been taking the medication ixekizumab for approximately 3 months (between 2 and 4 months) before the decision is made to add the study drug.
• People who are able to begin the study drug (tirzepatide) within 30 days of the treatment decision being made.

Who may not be able to join:

• People who have been taking ixekizumab for more than 4 months or fewer than 2 months.
• People who have previously taken tirzepatide or any GLP-1 receptor agonist medication, such as dulaglutide, liraglutide, or semaglutide (for example, medications like Ozempic or Victoza).
• People who are currently enrolled in another clinical trial.
• People who have a known allergy or sensitivity to any ingredient in tirzepatide.
• People with a personal or family history of a specific type of thyroid cancer called medullary thyroid cancer.
• People who have a condition called Multiple Endocrine Neoplasia type 2 (a rare hormonal disorder).
• People who have type 1 diabetes.
• People who have ever had inflammation of the pancreas (pancreatitis), whether short-term or long-term.
• People who have certain serious eye complications related to diabetes, including proliferative diabetic retinopathy, diabetic maculopathy, or a form of retinopathy requiring urgent treatment.
• People who have a history of a dangerous diabetic emergency involving very high blood sugar levels (ketoacidosis or hyperosmolar state/coma).
• People who have experienced a severe episode of low blood sugar without warning signs within the 6 months before the screening visit.
• People who have a history of serious digestive or stomach problems, including slow stomach emptying (gastroparesis), severe acid reflux, chronic indigestion, or ongoing nausea and vomiting.

Important: Always verify eligibility with the trial site directly before applying.